Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.

@article{GarcaLerma2001SusceptibilityOH,
  title={Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.},
  author={Jos{\'e} Gerardo Garc{\'i}a-Lerma and Soumya Nidtha and Walid Heneine},
  journal={The Journal of infectious diseases},
  year={2001},
  volume={184 4},
  pages={
          507-10
        }
}
Nucleoside reverse-transcriptase (RT) inhibitors (NRTIs), including lamivudine (3TC) and zidovudine (Zdv), are being evaluated for the treatment of human T cell lymphotropic virus type 1 (HTLV-1)-associated disease. However, information on the susceptibility of HTLV-1 to these drugs is limited. The activity of 5 NRTIs on HTLV-1 RT was evaluated. IC(50) values for Zdv, zalcitabine (ddC), didanosine (ddI), 3TC, and stavudine (d4T) were determined, using an enzymatic assay, for 5 HTLV-1 isolates… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-6 of 6 citations